Status:
COMPLETED
TRANSFORM-HF Ancillary Mechanistic Study
Lead Sponsor:
Inova Health Care Services
Collaborating Sponsors:
National Institutes of Health (NIH)
Duke University
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsem...
Detailed Description
Patients who are enrolling in the TRANSFORM-HF study or being prescribed Torsemide or Furosemide at hospital discharge will provide blood and urine at the time of study enrollment (within 72 hours of ...
Eligibility Criteria
Inclusion
- Participation in the TRANSFORM-HF trial or prescription of Torsemide or Furosemide
- Willing to provide blood and urine sample at enrollment and follow-up
Exclusion
- Inability or unwillingness to comply with the study requirements
Key Trial Info
Start Date :
December 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 30 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04702958
Start Date
December 10 2020
End Date
May 30 2023
Last Update
October 10 2023
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
2
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
3
Baltimore VA
Baltimore, Maryland, United States, 21201
4
University of Minnesota
Minneapolis, Minnesota, United States, 55455